Primecap Management Co. CA Sells 10,290 Shares of Sanofi (NASDAQ:SNY)

Key Points

• Primecap Management Co. reduced its stake in Sanofi by 0.9%, holding 1,100,638 shares valued at approximately $61 million as of its latest SEC filing.
• Several analysts have set new ratings and price targets for Sanofi, with a consensus rating of "Buy" and an average price target of $62.00.
• Sanofi reported a quarterly earnings miss with an EPS of $0.90, falling short of the consensus estimate of $0.96, amidst a 7% year-over-year revenue decline.

Primecap Management Co. CA lowered its stake in Sanofi (NASDAQ:SNY - Free Report) by 0.9% during the first quarter, according to the company in its most recent Form 13F filing with the SEC. The fund owned 1,100,638 shares of the company's stock after selling 10,290 shares during the quarter. Primecap Management Co. CA's holdings in Sanofi were worth $61,041,000 as of its most recent SEC filing.

Other institutional investors and hedge funds have also bought and sold shares of the company. Accent Capital Management LLC bought a new stake in shares of Sanofi in the 1st quarter valued at about $29,000. Eastern Bank raised its stake in Sanofi by 121.0% in the first quarter. Eastern Bank now owns 548 shares of the company's stock valued at $30,000 after buying an additional 300 shares during the period. Bessemer Group Inc. lifted its position in shares of Sanofi by 59.8% in the fourth quarter. Bessemer Group Inc. now owns 647 shares of the company's stock valued at $32,000 after buying an additional 242 shares during the last quarter. Golden State Wealth Management LLC boosted its stake in shares of Sanofi by 619.3% during the 1st quarter. Golden State Wealth Management LLC now owns 633 shares of the company's stock worth $35,000 after acquiring an additional 545 shares during the period. Finally, Brentview Investment Management LLC acquired a new position in shares of Sanofi during the 1st quarter worth approximately $42,000. Institutional investors own 14.04% of the company's stock.

Wall Street Analyst Weigh In

SNY has been the subject of several research reports. Morgan Stanley set a $56.00 price target on Sanofi in a report on Monday, June 2nd. Deutsche Bank Aktiengesellschaft reissued a "hold" rating on shares of Sanofi in a research report on Tuesday. JPMorgan Chase & Co. raised shares of Sanofi from a "neutral" rating to an "overweight" rating in a report on Friday. Guggenheim reiterated a "buy" rating on shares of Sanofi in a research note on Tuesday, June 3rd. Finally, Barclays restated an "overweight" rating on shares of Sanofi in a research report on Wednesday, July 2nd. Two equities research analysts have rated the stock with a hold rating, five have given a buy rating and three have issued a strong buy rating to the company's stock. According to MarketBeat, the company has a consensus rating of "Buy" and a consensus target price of $62.00.

Sanofi Stock Performance

NASDAQ:SNY traded down $0.28 during mid-day trading on Friday, reaching $47.16. 2,968,334 shares of the company's stock were exchanged, compared to its average volume of 2,427,230. Sanofi has a one year low of $44.73 and a one year high of $60.12. The company has a debt-to-equity ratio of 0.19, a quick ratio of 0.94 and a current ratio of 1.27. The business's fifty day simple moving average is $48.67 and its two-hundred day simple moving average is $51.97. The firm has a market capitalization of $115.79 billion, a PE ratio of 11.34, a price-to-earnings-growth ratio of 1.13 and a beta of 0.48.

Sanofi (NASDAQ:SNY - Get Free Report) last announced its earnings results on Thursday, July 31st. The company reported $0.90 EPS for the quarter, missing the consensus estimate of $0.96 by ($0.06). Sanofi had a return on equity of 16.86% and a net margin of 21.47%. The business had revenue of $11.34 billion for the quarter, compared to the consensus estimate of $9.91 billion. During the same period in the prior year, the business posted $1.73 earnings per share. The firm's revenue for the quarter was down 7.0% compared to the same quarter last year. Analysts anticipate that Sanofi will post 4.36 earnings per share for the current fiscal year.

Sanofi Profile

Sanofi, a healthcare company, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, Canada, and internationally. It operates through Pharmaceuticals, Vaccines, and Consumer Healthcare segments. The company provides specialty care, such as DUPIXENT, neurology and immunology, rare diseases, oncology, and rare blood disorders; medicines for diabetes and cardiovascular diseases; and established prescription products.